FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: GSK cuts 5,000 jobs; Codexis opens Singapore lab; Reliant sets IPO terms;and much more...

Tools

> The closure of a GlaxoSmithKline's Puerto Rican plant has kicked off the plan to cut 5,000 jobs. Report

> Codexis has opened a laboratory in Singapore, its first research facility in Asia. Release

> Reliant Pharmaceuticals has set its IPO terms at $25 to $27 a share. The company has raised more than $500 million from investors. Report

> Pharmion Corporation and MethylGene have reported preliminary clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar. Release

> It's official: the UK's National Health Service will start using Johnson & Johnson's Velcade under an unprecedented money-back-guarantee programReport

> Bristol-Myers Squibb's third-quarter results show what one big drug can do. Net income more than doubled to $858 million on revenues of $5.1 billion--and Plavix was the biggest reason. Report

> The European Union backed a trade protocol that will give poor countries better access to cheap generics in the event of an epidemic. Report

> The FDA slapped a new warning on Provigil, a drug for narcolepsy and other sleeping disorders made by Cephalon. Report

And Finally… Most people believe their sleep meds work better than the drugs actually do. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Bristol-Myers Squibb   Plavix   Biotech IPO   Asia   Codexis   Singapore   MethylGene   GlaxoSmithKline   Velcade  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.